Gold ticks up but remains pressured by Fed rate caution, easing trade fears
DUBLIN - Investment firm Citadel Group has disclosed a 1.98% stake in Avadel Pharmaceuticals plc, according to a regulatory filing published Friday.
The disclosure, made under Irish Takeover Panel rules, shows Citadel holds interests in 1,933,542 shares representing approximately 1.98% of Avadel’s common stock. The position includes 1,817,242 owned or controlled shares and 116,300 shares through stock-settled derivatives.
Citadel also disclosed short positions totaling 1,892,881 shares, or about 1.94% of the company. These short positions consist of 443,381 shares and 1,449,500 shares through stock-settled derivatives.
The filing details numerous transactions conducted on October 30, including both purchases and sales of Avadel common stock at prices ranging from approximately $18.72 to $18.89 per share.
The disclosure includes extensive options positions, with Citadel holding various put and call options with strike prices ranging from $5.00 to $35.00 and expiration dates extending from November 2025 to January 2027.
Irish Takeover Panel rules require disclosure of interests representing 1% or more of a company’s relevant securities. These disclosures provide transparency regarding significant shareholders during potential takeover situations.
The information was provided in a Form 8.3 filing, which is required for opening position disclosures under Irish takeover regulations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.